Alnylam Pharmaceuticals - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Alnylam Pharmaceuticals
ALNY
|
NASDAQ
|
United States
535
+37
Rank
$31.75B
Market Cap
$2.24B
+$ 0.42B
+23.08%
Revenue
$-0.24B
+$ 0.09B
-27.27%
Earnings
2.2K
+0.1K
+6.19%
Employees
About
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Amgen: A Biotech Bargain Heading Into Q3 Earnings
27.10.2026 -
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease
23.10.2026 -
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
22.10.2026 -
Alnylam Is Now Solidly Profitable. Why Are Investors Treating It Like a Broken Biotech?
21.10.2026 -
Alnylam (ALNY): Can the RNAi Franchise Get it an Entry into the S&P 500 Index?
20.10.2026